Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 61.70% | -15.47% | -49.07% | -58.05% | -66.56% |
| Total Depreciation and Amortization | 49.33% | 256.15% | 69.42% | -2.41% | -60.89% |
| Total Amortization of Deferred Charges | -100.00% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.47% | 564.39% | 632.09% | 351.88% | 261.19% |
| Change in Net Operating Assets | -397.22% | -13.41% | -29.91% | -590.21% | -230.69% |
| Cash from Operations | 43.12% | 19.33% | -10.59% | -37.77% | -42.28% |
| Capital Expenditure | 99.60% | 94.00% | -123.30% | -1,005.21% | -1,793.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.00% | 1,154.09% | 816.33% | 170.85% | 149.97% |
| Cash from Investing | 35.87% | 821.45% | 738.15% | 166.34% | 144.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -82.19% | -99.99% | -87.28% | -43.99% | -43.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 62.24% | 96.83% | 92.06% | 81.63% | 67.95% |
| Cash from Financing | -82.94% | -100.15% | -87.01% | -41.31% | -42.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.30% | 383.58% | 284.61% | 99.47% | 67.05% |